FDA Approves Expanded Indications for CF Drugs Alyftrek, Trikafta
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Tag: Alyftrek
FDA Approves Expanded Indications for CF Drugs Alyftrek, Trikafta
New label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Read More
NHS England to Offer Alyftrek for Cystic Fibrosis
England’s National Institute for Health and Care Excellence issued a positive final draft recommendation for Vertex Pharma’s Alyftrek CFTR modulator, which will now be available via the National Health Service (NHS).
Read More
European Commission Approves Vertex’s Alyftrek Once-Daily CFTR Modulator
Alyftrek is a triple combination CFTR modulator comprised of deutivacaftor, tezacaftor and vanzacaftor.
Read More
FDA Approves Alyftrek CFTR Modulator for Cystic Fibrosis
The FDA approved Alyftrek, a once-daily triple combo CFTR modulator, for certain cystic fibrosis patients aged 6 and older.
Read More